A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

India has the potential to increase exports of organic products up to Rs 20,000 crore in the next three years, Commerce and Industry Minister Piyush Goyal said on Thursday.

Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to <12 years and less than 30kg: morning dose of elexacaftor 100mg/tezacaftor 50mg/ivacaftor 75mg ...

Lupin’s ivacaftor oral granules receives US FDA tentative approval: Our Bureau, Mumbai Friday, January 10, 2025, 11:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) announ ...

In both trials, participants received oral ELX/TEZ/IVA daily (elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150mg in the evening) during a 4 week run-in period.

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...